T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.76B |
| 2 |
Cigna
CI
|
+$1.44B |
| 3 |
Bristol-Myers Squibb
BMY
|
+$1.26B |
| 4 |
Occidental Petroleum
OXY
|
+$763M |
| 5 |
Danaher
DHR
|
+$762M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$2.46B |
| 2 |
Wynn Resorts
WYNN
|
+$1.11B |
| 3 |
Netflix
NFLX
|
+$1.03B |
| 4 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$975M |
| 5 |
TWTR
Twitter, Inc.
TWTR
|
+$909M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.87% |
| 2 | Financials | 13.64% |
| 3 | Consumer Discretionary | 13.54% |
| 4 | Industrials | 10.67% |
| 5 | Technology | 10.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Alphabet (Google) Class C
GOOG
$4.07T
| $9.86B | 2.03% |
372,674,060
-2,665,955
| -0.7% | -$71.4M |
|
2
Amazon
AMZN
$2.48T
| $9.03B | 1.86% |
416,014,180
-20,677,720
| -5% | -$432M |
|
|
3
Danaher
DHR
$140B
| $7.34B | 1.51% |
127,531,159
+13,310,944
| +12% | +$762M |
|
|
AGN
4
DELISTED
Allergan plc
AGN
| $6.57B | 1.35% |
21,666,750
+1,892,527
| +10% | +$564M |
|
5
Booking.com
BKNG
$154B
| $6.22B | 1.28% |
135,060,725
+8,778,800
| +7% | +$419M |
|
6
Visa
V
$697B
| $6.09B | 1.25% |
90,728,110
-106,867
| -0.1% | -$7.24M |
|
|
7
Microsoft
MSFT
$2.92T
| $6.05B | 1.24% |
137,000,727
+82,364,204
| +151% | +$3.76B |
|
8
Apple
AAPL
$4.99T
| $6.02B | 1.24% |
191,841,252
-8,610,596
| -4% | -$275M |
|
9
Boeing
BA
$175B
| $5.52B | 1.13% |
39,770,667
+675,882
| +2% | +$98.6M |
|
10
Meta Platforms (Facebook)
META
$1.51T
| $5.17B | 1.06% |
60,250,602
+929,159
| +2% | +$75.9M |
|
11
McKesson
MCK
$104B
| $5.11B | 1.05% |
22,724,955
-136,353
| -0.6% | -$31.5M |
|
12
Gilead Sciences
GILD
$167B
| $5.07B | 1.04% |
43,313,403
-3,536,170
| -8% | -$386M |
|
|
ALXN
13
DELISTED
Alexion Pharmaceuticals
ALXN
| $4.74B | 0.97% |
26,202,535
+4,127,409
| +19% | +$712M |
|
14
Bausch Health
BHC
$1.69B
| $4.55B | 0.93% |
20,463,632
+338,296
| +2% | +$75M |
|
15
GE Aerospace
GE
$377B
| $4.28B | 0.88% |
33,628,984
+964,421
| +3% | +$125M |
|
16
Biogen
BIIB
$30.4B
| $4.23B | 0.87% |
10,473,787
-317,775
| -3% | -$128M |
|
17
JPMorgan Chase
JPM
$950B
| $4.15B | 0.85% |
61,226,069
-6,160,698
| -9% | -$402M |
|
18
UnitedHealth
UNH
$389B
| $4.12B | 0.85% |
33,775,752
+3,198,945
| +10% | +$378M |
|
19
Morgan Stanley
MS
$333B
| $4.08B | 0.84% |
105,087,346
+10,042,825
| +11% | +$382M |
|
20
Baidu
BIDU
$35.7B
| $3.81B | 0.78% |
19,118,097
-499,774
| -3% | -$102M |
|
|
MRSH
21
Marsh
MRSH
$91.7B
| $3.43B | 0.71% |
60,561,977
+6,359,489
| +12% | +$367M |
|
22
Mastercard
MA
$497B
| $3.43B | 0.71% |
36,682,331
+1,172,999
| +3% | +$108M |
|
23
Pfizer
PFE
$144B
| $3.4B | 0.7% |
106,993,290
+14,130,876
| +15% | +$461M |
|
|
CELG
24
DELISTED
Celgene Corp
CELG
| $3.2B | 0.66% |
27,642,475
-126,645
| -0.5% | -$14.5M |
|
|
25
Cigna
CI
$79.6B
| $3.17B | 0.65% |
19,544,960
+10,392,168
| +114% | +$1.44B |
|
Similar funds
T. Rowe Price Associates's Q2 2015 Portfolio in Review
As of Q2 2015, T. Rowe Price Associates held 2,615 positions worth $486B, up 0.44% from $484B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
T. Rowe Price Associates's Q2 2015 filing shows 76 new, 1,051 increased, 777 reduced and 79 closed positions. Its largest new stake was Allergan plc: 548,825 shares worth $570M. The largest sale was PHARMACYCLICS INC, an estimated $2.46B.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 21% a quarter earlier, followed by Financials and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2015 buy was Allergan plc: 548,825 shares worth $570M.
- T. Rowe Price Associates added most to Microsoft in Q2 2015, an estimated $3.76B increase.
- T. Rowe Price Associates's biggest Q2 2015 reduction was Wynn Resorts, cutting an estimated $1.11B.
- T. Rowe Price Associates fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.46B.
- T. Rowe Price Associates's ten largest holdings make up 14% of its $486B portfolio in Q2 2015.
- T. Rowe Price Associates opened 76 new positions and closed 79 in Q2 2015.
- T. Rowe Price Associates's portfolio value rose 0.44% quarter-over-quarter to $486B.
Based on T. Rowe Price Associates's 13F filing for Q2 2015, filed 14 Aug 2015.